Yunjun Xu
Overview
Explore the profile of Yunjun Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiang L, Hu J, Yan X, Yang H, Ji C, Xu Y, et al.
Adv Healthc Mater
. 2024 Jun;
14(4):e2401708.
PMID: 38875524
Despite laparoscopic-guided minimally invasive hepatectomy emerging as the primary approach for resecting hepatocellular carcinoma (HCC), there is still a significant gap in suitable biomaterials that seamlessly integrate with these techniques...
2.
Gong J, Hu J, Yan X, Xiang L, Chen S, Yang H, et al.
Small
. 2023 Jul;
20(3):e2300733.
PMID: 37452437
Relapse and unresectability have become the main obstacle for further improving hepatocellular carcinoma (HCC) treatment effect. Currently, single therapy for HCC in clinical practice is limited by postoperative recurrence, intraoperative...
3.
Song Y, Zhu Y, Jiang K, Liu X, Dong L, Li D, et al.
Nanoscale
. 2022 Dec;
15(1):365-375.
PMID: 36508179
Multifunctional magnet-fluorescent nanocomposites are widely applied in biomedical applications. Incorporating biocompatible quantum dots with highly ferrimagnetic magnetic nanoparticles into one nanoplatform for achieving efficient magnetic hyperthermia therapy (MHT) is very...
4.
Chen S, Song Y, Yan X, Dong L, Xu Y, Xuan S, et al.
J Nanobiotechnology
. 2022 Aug;
20(1):381.
PMID: 35986283
Bioactive materials have been extensively developed for the adjuvant therapy of cancer. However, few materials can meet the requirements for the postoperative resection of hepatocellular carcinoma (HCC) due to massive...
5.
Su Y, Hao L, Liu K, Zhang J, Dong L, Xu Y, et al.
RSC Adv
. 2022 May;
8(23):12944-12950.
PMID: 35541247
Upconversion core-shell nanoparticles have attracted a large amount of attention due to their multifunctionality and specific applications. In this work, based on a NaGdF sub-10 nm ultrasmall nanocore, a series...
6.
Yan X, Sun T, Song Y, Peng W, Xu Y, Luo G, et al.
Nano Lett
. 2022 Mar;
22(6):2251-2260.
PMID: 35254836
Current surgical single modality treatments for hepatocellular carcinoma (HCC) were restricted by recurrence, blood loss, significant trauma, and poor prognostic. Although multidisciplinary strategies for HCC treatment have been highly recommended...
7.
Yang H, Wang H, Wen C, Bai S, Wei P, Xu B, et al.
J Nanobiotechnology
. 2022 Mar;
20(1):98.
PMID: 35236363
Iron oxide nanoparticles (IONPs)-based contrast agents are widely used for T-weighted magnetic resonance imaging (MRI) in clinical diagnosis, highlighting the necessity and importance to evaluate their potential systematic toxicities. Although...
8.
Song Y, Li D, Lu Y, Jiang K, Yang Y, Xu Y, et al.
Natl Sci Rev
. 2021 Oct;
7(4):723-736.
PMID: 34692091
As a non-invasive therapeutic method without penetration-depth limitation, magnetic hyperthermia therapy (MHT) under alternating magnetic field (AMF) is a clinically promising thermal therapy. However, the poor heating conversion efficiency and...
9.
Bin J, Bai T, Zhao Q, Duan X, Deng S, Xu Y
J Recept Signal Transduct Res
. 2020 Oct;
41(5):451-456.
PMID: 33012239
Inflammation has been acknowledged as one of the pathological alterations in various cardiovascular disorders. Parkin has been found to be associated with mitochondrial protection. In the present study, we explored...
10.
Qian K, Song Y, Yan X, Dong L, Xue J, Xu Y, et al.
Biomaterials
. 2020 Aug;
259:120299.
PMID: 32827797
Due to the well-recognized biocompatibility, silk fibroin hydrogels have been developed for biomedical applications including bone regeneration, drug delivery and cancer therapy. For the treatment of cancer, silk-based photothermal agents...